API · CDMO · CRDMO
India's Outsourced Manufacturing Engine
From commodity APIs to innovator contract development & manufacturing — the China+1 beneficiary. Higher quality of earnings, sticky contracts and a long capex-led growth runway.
Reported · sourced (FY25)
What this shows
The 'picks-and-shovels' side of pharma: companies that make the raw drug ingredient (API) or manufacture/develop drugs for other companies under contract (CDMO/CRDMO). A big winner from the global 'China+1' supply-shift.
How to use it
The table ranks the listed API & CDMO players by size and quality. The three panels below explain where India is strong, where it's still weak, and the operating metrics that matter for these businesses.
Key terms
- API
- — Active Pharmaceutical Ingredient — the raw drug molecule, before it becomes a pill.
- CDMO
- — Contract Development & Manufacturing Org — makes products for innovators under contract.
- CRDMO
- — Adds 'Research' — also does the early discovery/development work (e.g. Syngene).
- China+1
- — Global drive to source outside China — India is a major beneficiary.
API + CDMO players
7
CDMO growth
14-16%
vs 8% API
CDMO margins
20-40%
sticky, premium
China+1 tailwind
Multi-year
supply de-risking
API & CDMO Universe
Sub-segment leaders with margins, returns and valuation
| Company | Sub-segment | Mkt cap | Rev CAGR 5Y | EBITDA% | ROCE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Divi's Laboratories | Generic API + Custom Synthesis (CDMO) | ₹1.8L Cr | 10% | 32% | 22% | 42.0x |
| Laurus Labs | ARV API + CDMO/CRDMO + Bio | ₹74.2K Cr | 18% | 20% | 17.8% | 30.0x |
| Piramal Pharma | Global CDMO + Complex Hospital + Consumer | ₹21.9K Cr | 0% | 16% | 7% | 18.0x |
| Neuland Laboratories | Specialty API + CMS (CDMO) | ₹21.7K Cr | 53% | 22% | 19% | 35.0x |
| Granules India | API + PFI + FD (Vertically Integrated) | ₹18.6K Cr | 19% | 21% | 15% | 14.0x |
| Syngene International | Integrated CRO + CDMO (Discovery to Manufacturing) | ₹18.1K Cr | -5% | 29% | 10.1% | 17.0x |
| Suven Pharmaceuticals (now Cohance Lifesciences) | CDMO (Pharma + Specialty Chem + ADC) | ₹16.5K Cr | -2% | 19% | 8.4% | 35.0x |
China+1 — where India is strong
- • Small-molecule API & intermediates at scale
- • Custom synthesis / process chemistry
- • Cost + English-language + IP regime
- • Growing peptide & sterile capability
Where India is still weak
- • Large-scale biologics / mammalian capacity
- • Cell & gene therapy infrastructure
- • Key starting materials still China-sourced
- • Highly complex ADC/conjugation at scale
What to track
- • Order book / backlog & book-to-bill
- • Projects by phase → commercial conversion
- • Customer concentration & repeat business
- • Capex pipeline & asset turns